Published in Cancer Res on April 09, 2014
Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia. Cancer Cell (2016) 1.44
GEMMs as preclinical models for testing pancreatic cancer therapies. Dis Model Mech (2015) 0.92
Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell. Oncotarget (2014) 0.91
Genomic organization and evolution of double minutes/homogeneously staining regions with MYC amplification in human cancer. Nucleic Acids Res (2014) 0.91
Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices. Sci Rep (2015) 0.90
Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research. BMC Med Genomics (2015) 0.90
Esophageal Cancer: Insights From Mouse Models. Cancer Growth Metastasis (2015) 0.88
Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics (2016) 0.87
Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling. PLoS Comput Biol (2015) 0.84
Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype. PLoS One (2015) 0.81
Human pluripotent stem cells on artificial microenvironments: a high content perspective. Front Pharmacol (2014) 0.81
Sustained conditional knockdown reveals intracellular bone sialoprotein as essential for breast cancer skeletal metastasis. Oncotarget (2014) 0.80
N-glycosylation Profiling of Colorectal Cancer Cell Lines Reveals Association of Fucosylation with Differentiation and Caudal Type Homebox 1 (CDX1)/Villin mRNA Expression. Mol Cell Proteomics (2015) 0.79
Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics. Mol Cancer Ther (2016) 0.79
Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays. Oncotarget (2016) 0.78
Establishment of Patient-derived Xenografts in Mice. Bio Protoc (2016) 0.78
Drug sensitivity in cancer cell lines is not tissue-specific. Mol Cancer (2015) 0.77
Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nat Protoc (2017) 0.77
Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents. Clin Cancer Res (2015) 0.77
Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems. BMC Cancer (2016) 0.76
Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine. Oncotarget (2016) 0.75
Assessing Specificity of Anticancer Drugs In Vitro. J Vis Exp (2016) 0.75
Towards a compendium of essential genes - From model organisms to synthetic lethality in cancer cells. Crit Rev Biochem Mol Biol (2015) 0.75
Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers. EMBO Mol Med (2017) 0.75
Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin. Leukemia (2016) 0.75
Procedure for Horizontal Transfer of Patient-Derived Xenograft Tumors to Eliminate Corynebacterium bovis. J Am Assoc Lab Anim Sci (2017) 0.75
Analysis of Wnt signalling dynamics during colon crypt development in 3D culture. Sci Rep (2015) 0.75
Global Conservation of Protein Status between Cell Lines and Xenografts. Transl Oncol (2016) 0.75
Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Sci Rep (2016) 0.75
A critical analysis of cancer biobank practices in relation to biospecimen quality. Biophys Rev (2015) 0.75
The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib. Oncotarget (2016) 0.75
Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM). Metabolomics (2016) 0.75
Automated microraft platform to identify and collect non-adherent cells successfully gene-edited with CRISPR-Cas9. Biosens Bioelectron (2016) 0.75
Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Front Cell Dev Biol (2016) 0.75
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. Gastroenterology (2017) 0.75
Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs. Pharmacol Rev (2017) 0.75
The Volume of Three-Dimensional Cultures of Cancer Cells InVitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors. Neoplasia (2017) 0.75
A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. Oncotarget (2016) 0.75
Zebrafish Xenograft: An Evolutionary Experiment in Tumour Biology. Genes (Basel) (2017) 0.75
Modeling of Patient Derived Xenografts in Colorectal Cancer. Mol Cancer Ther (2017) 0.75
A human genome diversity cell line panel. Science (2002) 14.11
Multigene amplification and massively parallel sequencing for cancer mutation discovery. Proc Natl Acad Sci U S A (2007) 3.93
Multiple rare variants in different genes account for multifactorial inherited susceptibility to colorectal adenomas. Proc Natl Acad Sci U S A (2004) 3.62
Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. Cancer Res (2003) 2.24
Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S A (2010) 2.22
Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci U S A (2006) 2.18
Mathematical modeling of cell population dynamics in the colonic crypt and in colorectal cancer. Proc Natl Acad Sci U S A (2007) 1.99
Rare variant hypothesis for multifactorial inheritance: susceptibility to colorectal adenomas as a model. Cell Cycle (2005) 1.92
The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A (2003) 1.79
Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull (2002) 1.53
Mutations in the AXIN1 gene in advanced prostate cancer. Eur Urol (2008) 1.53
Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1. Proc Natl Acad Sci U S A (2009) 1.20
Comprehensive assessment of variation at the transforming growth factor beta type 1 receptor locus and colorectal cancer predisposition. Proc Natl Acad Sci U S A (2010) 1.16
Nomenclature for Factors of the HLA System, 2004. Hum Immunol (2005) 1.14
Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. Proc Natl Acad Sci U S A (2008) 1.13
Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells. Proc Natl Acad Sci U S A (2011) 1.11
Examples of mathematical modeling: tales from the crypt. Cell Cycle (2007) 1.11
Germline mutations but not somatic changes at the MYH locus contribute to the pathogenesis of unselected colorectal cancers. Am J Pathol (2003) 1.08
Linkage disequilibrium and age of HLA region SNPs in relation to classic HLA gene alleles within Europe. Eur J Hum Genet (2010) 1.06
Genotyping possible polymorphic variants of human mismatch repair genes in healthy Korean individuals and sporadic colorectal cancer patients. Fam Cancer (2004) 0.99
On the proportion of cancer stem cells in a tumour. J Theor Biol (2010) 0.97
MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol (2003) 0.91
Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc Natl Acad Sci U S A (2012) 0.90
Nomenclature for factors of the HLA system, 2002. Hum Immunol (2002) 0.88
Stem cell differentiation and lumen formation in colorectal cancer cell lines and primary tumors. Cancer Res (2013) 0.87
Cyclin D1 rare variants in UK multiple adenoma and early-onset colorectal cancer patients. J Hum Genet (2010) 0.82
Nomenclature for factors of the HLA system, 2002. Eur J Immunogenet (2002) 0.81
Rapidly derived colorectal cancer cultures recapitulate parental cancer characteristics and enable personalized therapeutic assays. J Pathol (2014) 0.79
Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery. Int J Cancer (2002) 0.78
Commentary: Connections between genetics and statistics: a commentary on Fisher's 1951 Bateson lecture--'Statistical Methods in Genetics'. Int J Epidemiol (2010) 0.77
Replication error deficient and proficient colorectal cancer gene expression differences caused by 3'UTR polyT sequence deletions. Proc Natl Acad Sci U S A (2010) 0.76